Barclays PLC
BCS News Today: Stay Updated with the Latest Barclays PLC News in Real Time
Find BCS news now at Meyka AI. Stay informed with the latest Barclays PLC stocks updates, including price news, market analysis, and expert insights.
ITRM Iterum Therapeutics plc NASDAQ Q4 2025 results 03 Apr 2026: Earnings drivers and outlook
ITRM stock closed at $0.03 on 03 Apr 2026 after Q4 2025 results. Read Meyka AI earnings spotlight and short-term outlook for ITRM stock
Apollo 11 April 03: Archive Videos Rekindle Space-Stock Interest
Apollo 11 archive videos are spiking UK interest on 3 April, lifting attention on space-themed shares and funds. See how nostalgia can fuel short-term moves, the signals to track, and practical risk‑m
FECHF Fidelity China Special Situations (PNK) $3.49 02 Apr 2026: Watch catalysts
FECHF stock at **$3.49** on 02 Apr 2026 — high-volume mover with mixed metrics and clear catalysts
April 02: Maharashtra Extends Ladki Bahin e-KYC; 68 Lakh Accounts Shut
Maharashtra extends Ladki Bahin e-KYC correction to April 30 and shuts 68 lakh accounts for non-compliance. What it means for DBT compliance, Aadhaar KYC correction, banks, and beneficiaries in India,
M8H.DE MBH Corporation XETRA down 96.74% intraday 02 Apr 2026: liquidity warning
M8H.DE stock fell sharply intraday to **€0.037** on 02 Apr 2026; we examine drivers, risks and a €0.10 12‑month forecast
ARBKL $5.30 pre-market: watch Argo Blockchain (NASDAQ) oversold bounce on 02 Apr 2026
Pre-market oversold bounce setup for ARBKL stock at $5.30; watch volume and resistance levels for follow-through
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 18, 2026
Cowen maintained a Buy on AstraZeneca. Read the AZN analyst rating update, implications, and Meyka AI grade
Cowen Maintains Buy on SW Smurfit Westrock Plc March 18, 2026
Cowen maintains Buy on SW on March 18, 2026. Read the SW analyst rating, market cap, and Meyka grade B
Barclays Maintains Overweight on Incyte (INCY) Mar 2026
INCY analyst rating: Barclays maintained Overweight on Incyte in Mar 2026, implications for investors and price context